The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Abstract
Objective: To determine the impact of RAS mutation status on the traditional clinical score (t-CS) to predict survival after resection of colorectal liver metastases (CLM). Background: The t-CS relies on the following factors: primary tumor nodal status, disease-free interval, number and size of CLM, and carcinoembryonic antigen level. We hypothesized that the addition of RAS mutation status could create a modified clinical score (m-CS) that would outperform the t-CS. Methods: Patients who underwent resection of CLM from 2005 through 2013 and had RAS mutation status and t-CS factors available were included. Multivariate analysis was used to identify prognostic factors to include in the m-CS. Log-rank survival analyses were used to compare the t-CS and the m-CS. The m-CS was validated in an international multicenter cohort of 608 patients. Results: A total of 564 patients were eligible for analysis. RAS mutation was detected in 205 (36.3%) of patients. On multivariate analysis, RAS mutation was associated with poor overall survival, as were positive primary tumor lymph node status and diameter of the largest liver metastasis >50 mm. Each factor was assigned 1 point to produce a m-CS. The m-CS accurately stratified patients by overall and recurrence-free survival in both the initial patient series and validation cohort, whereas the t-CS did not. Conclusions: Modifying the t-CS by replacing disease-free interval, number of metastases, and CEA level with RAS mutation status produced an m-CS that outperformed the t-CS. The m-CS is therefore a simple validated tool that predicts survival after resection of CLM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Nordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjema, K., Bachellier, P., Jaeck, D., & Association Française de Chirurgie (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i · Cited by 1,722
Liver resection for colorectal metastases.
Fong, Y., Cohen, A. M., Fortner, J. G., Enker, W. E., Turnbull, A. D., Coit, D. G., Marrero, A. M., Prasad, M., Blumgart, L. H., & Brennan, M. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.938 · Cited by 1,284
Rees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., & John, T. G. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815aa2c2 · Cited by 1,026
Blazer, D. G., Kishi, Y., Maru, D. M., Kopetz, S., Chun, Y. S., Overman, M. J., Fogelman, D., Eng, C., Chang, D. Z., Wang, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5299 · Cited by 604
Self-citationRubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A. D., Andres, A., Audard, V., Sartoretti, P., Dousset, B., Majno, P. E., Soubrane, O., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl386 · Cited by 523
Kishi, Y., Abdalla, E. K., Chun, Y. S., Zorzi, D., Madoff, D. C., Wallace, M. J., Curley, S. A., & Vauthey, J.-N. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b674df · Cited by 516
Self-citation
Cited by
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Metadata
- Authors
- Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M. H., Song, J., Li, L., Dagenborg, V. J., Fretland, Å. A., Røsok, B., De Rose, A. M., Ardito, F., Edwin, B., Panettieri, E., Larocca, L. M., Yamashita, S., Conrad, C., Aloia, T. A., Poston, G. J., Bjørnbeth, B. A., & Vauthey, J.-N.
- Venue
- Annals of Surgery
- Published
- 2019-01
- Volume
- 269
- Issue
- 1
- Pages
- 120-126
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W2617021687
- Cited by
- 260
- References
- 29
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. https://app.cochat.ai/papers/10.1097/sla.0000000000002319
- The paper
- Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M. H., Song, J., Li, L., Dagenborg, V. J., Fretland, Å. A., Røsok, B., De Rose, A. M., Ardito, F., Edwin, B., Panettieri, E., Larocca, L. M., Yamashita, S., Conrad, C., Aloia, T. A., . . . Vauthey, J.-N. (2019). RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.